Academic radiology · 2021
Application of Compressed Sensing 3D MR cholangiopancreatography (CS-MRCP) with Contact-Free Physiological Monitoring (CFPM) for Pancreaticobiliary Disorders.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Ming, Xu Jin, Wu Qiaoling, Wang Xiheng, Ren Jing, Wang Xiaoqi, Xue Huadan, Jin Zhengyu
Аннотация
RATIONAL AND OBJECTIVES: To prospectively evaluate the clinical feasibility of the magnetic resonance cholangiopancreatography (MRCP) protocol using both contact-free physiological monitoring (CFPM) and compressed sensing (CS) (CS-CFPM-MRCP) and to compare its performance with that of the standard navigator-triggered (NT) CS-NT-MRCP and NT-MRCP.
MATERIALS AND METHODS: A total of 63 patients (36 males, 27 females, age range: 18-83 years, mean age: 52.30 ± 15.70 years) suspected with duct-related pathologies were prospectively enrolled and performed the three MRCP protocols randomly. The acquisition time was compared. The pancreaticobiliary system was divided into 12 segments and evaluated based on a five-point Likert scale and compared by the Friedman test with a post hoc test. The diagnostic performance of the 3 MRCP was evaluated by the AUC value and compared by Delong's test. The interobserver agreement was evaluated by Kendall's W test.
RESULTS: Compared to NT-MRCP, the acquisition time of CS-NT-MRCP and CS-CFPM-MRCP was significantly decreased (both p < 0.001). There is no significant difference in the overall imaging quality (p > 0.05) between the NT-MRCP and CS-CFPM-MRCP protocols. CS-CFPM-MRCP depicted pancreatic duct and intrahepatic ducts better than CS-NT-MRCP (all p < 0.05) and was comparable with that of the NT-MRCP (all p > 0.05). For identification of abnormalities and diseases associated with MPD anatomy, the mean AUC value for NT-MRCP and CS-CFPM-MRCP were 0.896 (95%CI: 0.834, 0.958) and 0.905 (95%CI: 0.846, 0.964), which were significantly higher when compared to that for CS-NT-MRCP (0.713 [95%CI:0.622, 0.805]) (p = 0.001 and < 0.001). All evaluations showed good to excellent agreement (0.619-0.897).
CONCLUSION: The combination of CS and CFPM is considered feasible for shortening the scan time of 3D free breath MRCP without impairing the imaging quality and CS-CFPM-MRCP is considered feasible for patients suspected with pancreaticobiliary diseases.
MATERIALS AND METHODS: A total of 63 patients (36 males, 27 females, age range: 18-83 years, mean age: 52.30 ± 15.70 years) suspected with duct-related pathologies were prospectively enrolled and performed the three MRCP protocols randomly. The acquisition time was compared. The pancreaticobiliary system was divided into 12 segments and evaluated based on a five-point Likert scale and compared by the Friedman test with a post hoc test. The diagnostic performance of the 3 MRCP was evaluated by the AUC value and compared by Delong's test. The interobserver agreement was evaluated by Kendall's W test.
RESULTS: Compared to NT-MRCP, the acquisition time of CS-NT-MRCP and CS-CFPM-MRCP was significantly decreased (both p < 0.001). There is no significant difference in the overall imaging quality (p > 0.05) between the NT-MRCP and CS-CFPM-MRCP protocols. CS-CFPM-MRCP depicted pancreatic duct and intrahepatic ducts better than CS-NT-MRCP (all p < 0.05) and was comparable with that of the NT-MRCP (all p > 0.05). For identification of abnormalities and diseases associated with MPD anatomy, the mean AUC value for NT-MRCP and CS-CFPM-MRCP were 0.896 (95%CI: 0.834, 0.958) and 0.905 (95%CI: 0.846, 0.964), which were significantly higher when compared to that for CS-NT-MRCP (0.713 [95%CI:0.622, 0.805]) (p = 0.001 and < 0.001). All evaluations showed good to excellent agreement (0.619-0.897).
CONCLUSION: The combination of CS and CFPM is considered feasible for shortening the scan time of 3D free breath MRCP without impairing the imaging quality and CS-CFPM-MRCP is considered feasible for patients suspected with pancreaticobiliary diseases.